FARXIGA in Cardiology
FARXIGA helps save lives in patients by reducing CV death and hospitalization for heart failure.1
FARXIGA is now recommended as a component of first-line therapy according to the 2021 ACC Expert Consensus Decision Pathway.2,*,†
Start FARXIGA today in your newly diagnosed patients with HFrEF who are on an ACEI/ARB.
*2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction.
†SGLT2i is recommended as first-line therapy; FARXIGA is the only SGLT2i FDA approved for use in patients with HFrEF with and without T2D as discussed in the 2021 ACC Expert Consensus Decision Pathway.2
Mortality due to heart failure is on the rise in the US3
In the US, we’ve seen a 38% increase in deaths between 2011 and 2017* in which heart failure was the underlying cause.3,† That’s one reason to remember that every patient with HFrEF remains at substantial risk and can deteriorate suddenly.4 Also consider that over 95% of patients hospitalized with HFrEF died or were readmitted within 5 years,5,‡ while approximately 1 in 8 ambulatory patients with HFrEF died without any signs of worsening heart failure within 3 years.6,§
Total number of deaths due to heart failure in the US: 2011 and 2017*
Every patient with HFrEF remains at substantial risk and can deteriorate suddenly4
Is there more that can be done today to help protect your newly diagnosed patients with HFrEF from CV death?
ACC=American College of Cardiology; ACEI=angiotensin-converting enzyme inhibitor; ARB=angiotensin II receptor blocker; CKD=chronic kidney disease; CV=cardiovascular; FDA=US Food and Drug Administration; HFrEF=heart failure with reduced ejection fraction; SGLT2i=sodium-glucose cotransporter 2 inhibitor; T2D=type 2 diabetes.
You are about to leave the FARXIGA website